Distorted expression of dopamine receptor genes in systemic lupus erythematosus

Immunobiology

Volumn 218, Issue 7, 2013, Pages 979-983

  Jafari, Mohieddin ^a,b   Ahangari, Ghasem ^b   Saberi, Mohammad ^b   Samangoui, Shahindokht ^c   Torabi, Raheleh ^b   Zouali, Moncef ^d,e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d INSERMu606   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Dopamine; Real time PCR; T cells

Indexed keywords

BETA ACTIN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL SELECTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DR1 GENE; DR2 GENE; DR3 GENE; DR4 GENE; DR5 GENE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOREGULATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADULT; B-LYMPHOCYTES; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RECEPTORS, DOPAMINE; T-LYMPHOCYTES;

EID: 84877135162     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.11.002     Document Type: Article

References (52)

1. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., Weiss R., Cooper T.B., Mann J.J., Van Heertum R.L., Gorman J.M., Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8104-8109.
2. Barbanti P., Bronzetti E., Ricci A., Cerbo R., Fabbrini G., Buzzi M.G., Amenta F., Lenzi G.L. Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine?. Neurosci. Lett. 1996, 207:73-76.
3. Barbanti P., Fabbrini G., Ricci A., Bruno G., Cerbo R., Bronzetti E., Amenta F., Luigi Lenzi G. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. Mech. Ageing Dev. 2000, 120:65-75.
4. Basu S., Dasgupta P.S. Dopamine, a neurotransmitter, influences the immune system. J. Neuroimmunol. 2000, 102:113-124.
5. Bergquist J., Josefsson E., Tarkowski A., Ekman R., Ewing A. Measurements of catecholamine-mediated apoptosis of immunocompetent cells by capillary electrophoresis. Electrophoresis 1997, 18:1760-1766.
6. Bergquist J., Tarkowski A., Ekman R., Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:12912-12916.
7. Bergquist J., Tarkowski A., Ewing A., Ekman R. Catecholaminergic suppression of immunocompetent cells. Immunol. Today 1998, 19:562-567.
8. Besser M.J., Ganor Y., Levite M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J. Neuroimmunol. 2005, 169:161-171.
9. Blalock J.E. The syntax of immune-neuroendocrine communication. Immunol. Today 1994, 15:504-511.
10. Blank M., Krause I., Buskila D., Teitelbaum D., Kopolovic J., Afek A., Goldberg I., Shoenfeld Y. Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell. Immunol. 1995, 162:114-122.
11. Carr L., Tucker A., Fernandez-Botran R. In vivo administration of l-dopa or dopamine decreases the number of splenic IFN gamma-producing cells. J. Neuroimmunol. 2003, 137:87-93.
12. Cohen-Solal J., Diamond B. Lessons from an anti-DNA autoantibody. Mol. Immunol. 2011, 48:1328-1331.
13. + regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 2007, 109:632-642.
14. Cosentino M., Zaffaroni M., Marino F., Bombelli R., Ferrari M., Rasini E., Lecchini S., Ghezzi A., Frigo G. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J. Neuroimmunol. 2002, 133:233-240.
15. Deng Y., Tsao B.P. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat. Rev. Rheumatol. 2010, 6:683-692.
16. DiMaio S., Grizenko N., Joober R. Dopamine genes and attention-deficit hyperactivity disorder: a review. J. Psychiatry Neurosci. 2003, 28:27-38.
17. Elbourne K.B., Keisler D., McMurray R.W. Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus. Lupus 1998, 7:420-427.
18. Ferrari M., Termine C., Franciotta D., Castiglioni E., Pagani A., Lanzi G., Marino F., Lecchini S., Cosentino M., Balottin U. Dopaminergic receptor D5 mRNA expression is increased in circulating lymphocytes of Tourette syndrome patients. J. Psychiatr. Res. 2008, 43:24-29.
19. Ghosh M.C., Mondal A.C., Basu S., Banerjee S., Majumder J., Bhattacharya D., Dasgupta P.S. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int. Immunopharmacol. 2003, 3:1019-1026.
20. Giorelli M., Livrea P., Trojano M. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. J. Interferon Cytokine Res. 2005, 25:395-406.
21. Ilani T., Ben-Shachar D., Strous R.D., Mazor M., Sheinkman A., Kotler M., Fuchs S. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:625-628.
22. Ilani T., Strous R.D., Fuchs S. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J. 2004, 18:1600-1602.
23. Jameson S.C. Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2002, 2:547-556.
24. Karpuzoglu E., Zouali M. The multi-faceted influences of estrogen on lymphocytes: toward novel immuno-interventions strategies for autoimmunity management. Clin. Rev. Allergy Immunol. 2011, 40:16-26.
25. + regulatory T-cell activity: implications for neurodegeneration. J. Neurosci. 2004, 24:6133-6143.
26. Kuo C.T., Veselits M.L., Leiden J.M. LKLF: a transcriptional regulator of single-positive T cell quiescence and survival. Science 1997, 277:1986-1990.
27. Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr. Opin. Pharmacol. 2008, 8:460-471.
28. Levite M., Chowers Y., Ganor Y., Besser M., Hershkovits R., Cahalon L. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. Eur. J. Immunol. 2001, 31:3504-3512.
29. McKenna F., McLaughlin P.J., Lewis B.J., Sibbring G.C., Cummerson J.A., Bowen-Jones D., Moots R.J. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 2002, 132:34-40.
30. McMurray R., Keisler D., Kanuckel K., Izui S., Walker S.E. Prolactin influences autoimmune disease activity in the female B/W mouse. J. Immunol. 1991, 147:3780-3787.
31. McMurray R.W., Allen S.H., Pepmueller P.H., Keisler D., Cassidy J.T. Elevated serum prolactin levels in children with juvenile rheumatoid arthritis and antinuclear antibody seropositivity. J. Rheumatol. 1995, 22:1577-1580.
32. Meredith E.J., Chamba A., Holder M.J., Barnes N.M., Gordon J. Close encounters of the monoamine kind: immune cells betray their nervous disposition. Immunology 2005, 115:289-295.
33. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
34. Nagai Y., Ueno S., Saeki Y., Soga F., Hirano M., Yanagihara T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 1996, 46:791-795.
35. Nakano K., Higashi T., Hashimoto K., Takagi R., Tanaka Y., Matsushita S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 2008, 373:286-291.
36. Nakano K., Higashi T., Takagi R., Hashimoto K., Tanaka Y., Matsushita S. Dopamine released by dendritic cells polarizes Th2 differentiation. Int. Immunol. 2009, 21:645-654.
37. Ostadali M.R., Ahangari G., Eslami M.B., Razavi A., Zarrindast M.R., Ahmadkhaniha H.R., Boulhari J. The detection of dopamine gene receptors (DRD1-DRD5) expression on human peripheral blood lymphocytes by real time PCR. Iran. J. Allergy Asthma Immunol. 2004, 3:169-174.
38. Pacheco R., Prado C.E., Barrientos M.J., Bernales S. Role of dopamine in the physiology of T-cells and dendritic cells. J. Neuroimmunol. 2009, 216:8-19.
39. Peeva E., Grimaldi C., Spatz L., Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. J. Clin. Invest. 2000, 106:1373-1379.
40. Qiu Y.H., Cheng C., Dai L., Peng Y.P. Effect of endogenous catecholamines in lymphocytes on lymphocyte function. J. Neuroimmunol. 2005, 167:45-52.
41. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N. Engl. J. Med. 2008, 358:929-939.
42. Ricci A., Amenta F. Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J. Neuroimmunol. 1994, 53:1-7.
43. Ricci A., Bronzetti E., Mignini F., Tayebati S.K., Zaccheo D., Amenta F. Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J. Neuroimmunol. 1999, 96:234-240.
44. Sakic B., Lacosta S., Denburg J.A., Szechtman H. Altered neurotransmission in brains of autoimmune mice: pharmacological and neurochemical evidence. J. Neuroimmunol. 2002, 129:84-96.
45. Sarkar C., Basu B., Chakroborty D., Dasgupta P.S., Basu S. The immunoregulatory role of dopamine: an update. Brain Behav. Immun. 2010, 24:525-528.
46. Sarkar C., Das S., Chakroborty D., Chowdhury U.R., Basu B., Dasgupta P.S., Basu S. Cutting edge: stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J. Immunol. 2006, 177:7525-7529.
47. Stockinger B., Barthlott T., Kassiotis G. The concept of space and competition in immune regulation. Immunology 2004, 111:241-247.
48. Takahashi N., Nagai Y., Ueno S., Saeki Y., Yanagihara T. Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett. 1992, 314:23-25.
49. Tsao C.W., Lin Y.S., Cheng J.T. Effect of dopamine on immune cell proliferation in mice. Life Sci. 1997, 61:PL361-PL371.
50. Walker S.E., McMurray R.W., Houri J.M., Allen S.H., Keisler D., Sharp G.C., Schlechte J.A. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann. N.Y. Acad. Sci. 1998, 840:762-772.
51. + T cells via dopamine receptor D3. J. Immunol. 2006, 176:848-856.
52. Zouali M. Epigenetics in lupus. Ann. N.Y. Acad. Sci. 2011, 1217:154-165.